Mcl-1 is considered as the primary venetoclax-resistant factor and inhibition of Mcl-1 could reverse venetoclax resistance in various hematologic cancers (Ramsey et al. 2018). This evidence concerns the gene MCL1 and hematopoietic and lymphoid cell neoplasm.